Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 19/20 | 1.00 |
| ▸ | BTD | P43251 | 1/20 | 0.68 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.62 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.62 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20185850 | 0.90 | VNN1 (1.00) | VNN1BTDHDAC3HDAC1HDAC2 | |
| SCHEMBL20185763 | 0.89 | VNN1 (1.00) | VNN1HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL21381210 | 0.85 | VNN1 (0.74) | VNN1BTDHDAC3HDAC1HDAC2 | |
| SCHEMBL20185780 | 0.84 | VNN1 (1.00) | VNN1BTD | |
| SCHEMBL20185765 | 0.84 | VNN1 (1.00) | VNN1BTD | |
| SCHEMBL18286249 | 0.82 | VNN1 (1.00) | VNN1BTD | |
| SCHEMBL18286265 | 0.81 | VNN1 (1.00) | VNN1BTD | |
| SCHEMBL18286263 | 0.81 | VNN1 (1.00) | VNN1BTDHDAC3HDAC1HDAC2 | |
| SCHEMBL20185849 | 0.80 | VNN1 (1.00) | VNN1BTD | |
| SCHEMBL20185816 | 0.78 | VNN1 (1.00) | VNN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190292157-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF VANIN-1 ENZYME | PFIZER INC. (US) | 2019-09-26 | — | — | US | claimed |
| US-10308615-B2 | Heterocyclic compounds as inhibitors of Vanin-1 enzyme | PFIZER INC. (US) | 2019-06-04 | — | — | US | claimed |
| US-20180148420-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF VANIN-1 ENZYME | PFIZER INC. (US) | 2018-05-31 | — | — | US | claimed |
| EP-3303303-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF VANIN-1 ENZYME | Pfizer Inc (US) | 2018-04-11 | — | — | EP | claimed |
| WO-2016193844-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF VANIN-1 ENZYME | PFIZER INC. (US) | 2016-12-08 | — | — | WO | claimed |
| US-20190292157-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF VANIN-1 ENZYME | PFIZER INC. (US) | 2019-09-26 | — | — | US | disclosed |
| US-20190292157-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF VANIN-1 ENZYME | PFIZER INC. (US) | 2019-09-26 | — | — | US | disclosed |
| US-10308615-B2 | Heterocyclic compounds as inhibitors of Vanin-1 enzyme | PFIZER INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-10308615-B2 | Heterocyclic compounds as inhibitors of Vanin-1 enzyme | PFIZER INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180148420-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF VANIN-1 ENZYME | PFIZER INC. (US) | 2018-05-31 | — | — | US | disclosed |
| US-20180148420-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF VANIN-1 ENZYME | PFIZER INC. (US) | 2018-05-31 | — | — | US | disclosed |
| US-20180148420-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF VANIN-1 ENZYME | PFIZER INC. (US) | 2018-05-31 | — | — | US | disclosed |
| EP-3303303-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF VANIN-1 ENZYME | Pfizer Inc (US) | 2018-04-11 | — | — | EP | disclosed |
| WO-2016193844-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF VANIN-1 ENZYME | PFIZER INC. (US) | 2016-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292157-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF VANIN-1 ENZYME | VNN1, VAT1, CMA1 | VNN1 1/4885BTD 97/4885HDAC3 1227/4885 |
| US-10308615-B2 | Heterocyclic compounds as inhibitors of Vanin-1 enzyme | VNN1, MVD, VAT1 | VNN1 1/4885BTD 121/4885HDAC3 1146/4885 |
| US-20180148420-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF VANIN-1 ENZYME | VNN1, CMA1, VAT1 | VNN1 1/4885BTD 181/4885HDAC3 1537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.